Radiotherapy is used for 50% of the cancer treatments. Despite important technological improvements, secondary effects remain significant due to lack of tumor selectivity and/or radioresistance. A new strategy combining radiation with tumor targeted nanoagents to improve tumor diagnostic and therapeutic index of radiations has emerged. The potential of theranostic platinum nanoparticles will be presented.
Sandrine LACOMBE is full professor at U.Paris Saclay, expert in the development of theranostic nanoparticles for radiation therapies. She’s leading a research group in the Institute of Molecular sciences (CNRS). She obtained her PhD in science at U Paris Sud and she performed a postdoc with a Fritz-Haber fellowship in the group of Prof Ertl, Nobel prize 2007, at the Fritz-Haber Institut Berlin, Germany. She was invited researcher at the Sherbrooke university hospital (Canada), the nuclear center of Bariloche (Argentina) and the Sydney university (Australia). She ‘ leading the interdisciplinary institute for innovative radiation strategies iNanotheRad, which merges the community of radiooncologists, medical physicists, chemists, biologists, physicists, engineers of Paris Saclay.
